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Abstract
Background: Current evidence shows that the CD40–CD40 ligand (CD40–CD40L) system plays a crucial role in the
development, progression and outcome of systemic lupus erythematosus (SLE). The aim of this study was to
investigate whether a CD40 gene single nucleotide polymorphism (SNP) is associated with SLE and CD40 expression in
the Chinese population. We included controls (n = 220) and patients with either SLE (n =205) in the study.
Methods: The gene polymorphism was measured using Snapshot SNP genotyping assays and confirmed by sequencing.
We analyzed three single nucleotide polymorphisms of CD40 gene rs1883832C/T, rs1569723A/C and rs4810485G/T in 205
patients with SLE and 220 age-and sex-matched controls. Soluble CD40 (sCD40) levels were measured by ELISA.
Results: There were significant differences in the genotype and allele frequencies of CD40 gene rs1883832C/T
polymorphism between the group of patients with SLE and the control group (P < 0.05). sCD40 levels were increased in
patients with SLE compared with controls (P < 0.01). Moreover, genotypes carrying the CD40 rs1883832 C/T variant allele
were associated with increased CD40 levels compared to the homozygous wild-type genotype in patients with SLE. The
rs1883832C/T polymorphism of CD40 and its sCD40 levels were associated with SLE in the Chinese population.
Conclusions: Our results suggest that CD40 gene may play a role in the development of SLE in the Chinese population.
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Background
Systemic lupus erythematosus (SLE) a kind of chronic
autoimmune disease, leading to multiple organ damage,
has the characteristics of various autoantibodies produc-
tion. Although that the etiology and pathogenesis of SLE
is not clear, it maybe immune regulation disorder caused
by a complex interplay of genetic and environmental
factors, hormones, antigen antibody and complement
complex deposits lead to local or systemic tissue or
organ damage [1–4]. Among them, genetic factors seem
to play a key role in the susceptibility to SLE. In the past
several years genome-wide association studies (GWAS)
for SLE have identified literally hundreds of genetic loci
involved in the susceptibility conferred to complex inher-
ited traits [5–7]. Even though this scenario represents an
extraordinary advance in complex disease genetics, the
modest effect sizes of the common polymorphisms found
associated explain only a small fraction of the heritability
in most of these multifactorial conditions, suggesting that
many more loci remain to be discovered [8, 9]. One of the
genes encoding a member of the tumor necrosis factor
receptor family that plays a key role in adaptive immunity
of SLE is CD40 [10].
CD40, a member of the tumor necrosis family of
transmembrane glycoproteins, was identified on B cells,
monocytes, dendritic cells, endothelial and epithelial
cells, which is rapidly and transiently expressed on the
surface of recently activated CD4+T cells and is a potent
T-cell costimulatory molecule [11–13]. Interactions
between CD40 and CD40L induce B cell immunoglo-
bulin production as well as monocyte activation and
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dendrite cell differentiation [14, 15]. Some authors have
demonstrated that the multipotent immunomodulator
CD40, expressed on vascular endothelial cells, smooth
muscle cells, mononuclear phagocytes, and platelets, pro-
mote awide array of pro-atherogenic functions in vitro
[16–19]. The gene encoding CD40 is located on chromo-
some 20q11-13 in humans, which consists of nine exons
and eight Introns. Recently, a number of polymorphisms
in the gene encoding CD40 gene have been identified and
a relationship between the CD40 gene polymorphisms
and risk of different autoimmune and inflammatory
diseases, such as multiple autoimmune diseases, Graves’
disease and rheumatoid arthritis has been reported
[20–22]. However, very little data has examined the
association between rs1883832C/T, rs1569723A/C and
rs4810485G/T polymorphisms in CD40 gene and SLE.
Furthermore, the relationship between the CD40 gene
polymorphisms and the plasma level of CD40 gene is
unknown. In this study, we investigated the relation-
ship of CD40 gene rs1883832C/T, rs1569723A/C and
rs4810485G/T polymorphisms and their CD40 serum
levels in a Chinese population.
Methods
Study population
Our study was designed as a retrospective study. The
study consisted of 205 patients with SLE (36 males and
169 females, aged between 30 and 82 years). All patients
with SLE were consecutively selected. They were recruited
from the Department of Dermatology, Affiliated Hospital
of Youjiang Medical University for Nationalities, Guangxi,
China between October 2014 and November 2015. The
220 control subjects were matched to the patients on the
basis of age and gender (42 males and 178 females, aged
between 29 and 78 years). The control subjects underwent
a routine medical check-up in the outpatient clinic of the
Department of Internal Medicine, Affiliated Hospital of
Youjiang Medical University for Nationalities, Guangxi,
China between May 2013 and November 2014. According
to the thorough clinical and laboratory evaluation, none of
them were found to have any medical condition other
than hypertension, autoimmune and inflammatory
diseases. All study subjects were Chinese and resided
in the same geographic area in China. The study was
performed with the approval of the ethics committee
of the Affiliated Hospital of Youjiang Medical University
for Nationalities, and written informed consent was ob-
tained from all the subjects.
DNA extraction
Genomic DNA was extracted from EDTA-anticoagulated
peripheral blood leukocytes by the salting-out method
[23]. Briefly, 3 ml of blood was mixed with Triton lysis
buffer (0.32 M sucrose, 1 % Triton X100, 5 mM MgCl2,
H2O, 10 mM Tris–HCl, pH 7.5). Leucocytes were spun
down and washed with H2O. The pellet was incubated
with proteinase K at 56 °C and subsequently salted out at
4 °C using a saturated NaCl solution. Precipitated proteins
were removed by centrifugation. The DNA in the super-
natant fluid was dissolved in 300 μlH2O.
Determination of CD40 genotype
The CD40 gene rs1883832 C/T, rs1569723 A/C and
rs4810485 G/T genotypes were determined by using a
Snapshot SNP genotyping assay. The PCR primers
were designed based on the GenBank reference sequence
(accession no. NC_000020.11) (Table 1). To confirm the
genotyping results, PCR-amplified DNA samples were
examined by DNA sequencing, and the results were
100 % concordant.
Plasma CD40 determination
Plasma samples from the patients and healthy controls
were separated from venous blood at room temperature,
and stored at −70 °C until use. The quantity determination
of plasma CD40 levels was performed by enzyme-linked
immunosorbent assay (ELISA) kits (Fermentas, Lithuania),
following the manufacturer’s protocol. Developed color re-
action was measured as OD450 units on an ELISA reader
(RT-6000, China). The concentration of plasma CD40 was
determined by using standard curve constructed with the
kit’s standards over the range of 0–1000 pg/ml.
Statistical analysis
Genotype and allele frequencies of CD40 were compared
between SLE cases and controls using the χ2 test and
Fisher’s exact test when appropriate, and odds ratios
(OR) and 95 % confidence intervals (CIs) were calculated
to assess the relative risk conferred by a particular allele
and genotype. Demographic and clinical data between
Table 1 The primer sequences used for detecting the different
CD40 SNPs
Reference SNP ID PCR primers
rs1883832C/T F:5'-GGACCTGGGGGCAAAGAAGA-3'
R: 5'- CCCACTCCCAACTCCCGTCT -3'
EF:5'-TTTTTTTTTTTTGCAGAGGCAGAC
GAACCAT -3'
rs1569723 A/C F: 5'- GGGATG GCCTGATCCAAAGG -3'
R: 5'- CCCACAGTCCACCACCCATC -3'
EF:5'-TTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTCGCTTTACACCCACAGCC-3'
rs4810485 G/T F: 5'- ATCCCCCAAGTACCTGGCTCCT -3'
R: 5'- CCTTGCTGCTTCCC TTGCTTTC -3'
EF:5'- TTTTTTTTTTTTTTTTTTTTTTTTTTT
TCCTACTTTAGAG GGCTGTAGATTCC -3'
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groups were compared by χ2 test and by Student’s t-test.
Hardy–Weinberg equilibrium was tested for with a
goodness of fit χ2-test with 1 ° of freedom to compare
the observed genotype frequencies among the subjects
with the expected genotype frequencies. The linkage
disequilibrium (LD) between the polymorphisms was
quantified using the Shi’s standardized coefficient D'
(|D'|) [24]. The haplotypes and their frequencies were
estimated based on a Bayesian algorithm using the Phase
program [25]. Statistical significance was assumed at the
P < 0.05 level. The SPSS statistical software package
version 11.5 was used for all of the statistical analysis.
Results
Clinical characteristics of the study participants
There were no significant differences in the age (P > 0.05)
and percentage of males/females (P > 0.05) between the
two groups. The serum CD40 levels were significantly
higher in the group of patients with SLE than those
in the control group [(mean +/− SD 58.5 +/−
22.8 pg/ml, n = 205) vs, (mean +/− SD 41.7 +/−
13.2 pg/ml, n = 220); P <0.001] (Fig. 1).
The genotype and allele frequencies of CD40 gene
The genotype and allele frequencies of the CD40 gene
rs1883832 C/T, rs1569723 A/C and rs4810485 G/T
polymorphisms in the group of patients with SLE and in
the control group are shown in Table 2. The genotype
distributions of the three polymorphisms among the con-
trols and the cases were in Hardy–Weinberg equilibrium,
and the Hardy–Weinberg equilibrium p-values of the CC,
CT and TT genotypes of rs1883832 C/T, rs1569723 A/C
and rs4810485 G/T were 0.440, 0.509 and 0.686 in con-
trols, and were 0.718, 0.195 and 0.300 in cases, respect-
ively. The frequencies of the CC, CT and TT genotypes of
rs1883832 C/T were 35.9, 45.9 and 18.2 % in controls, and
were 22.9, 51.2 and 25.9 % in cases, respectively. There
were significant differences in the genotype and allele fre-
quencies of the CD40 gene rs1883832 C/T polymorphism
between the SLE and control groups. The rs1883832 T al-
lele was associated with a significantly increased risk of
SLE as compared with the rs1883832 C allele (OR = 1.517,
95 % CI, 1.157–1.990, P = 0.003). However, genotype and
allele frequencies of the CD40 gene rs1569723 A/C and
rs4810485 G/T polymorphisms in SLE patients were not
significantly different than those in controls (P > 0.05).
Haplotype analysis of the CD40 gene
Haplotype analyses were performed and the possible six
haplotype frequencies are shown in Table 3. Two major
haplotypes (TCT and CAG) accounted for 51.5, 42.9 and
43.0, 47.0 % of these six haplotypes in both the cases and
the controls, respectively. CD40 gene rs1883832 C/T
polymorphism was in strong linkage disequilibrium
with the rs1569723 A/C (|D'| = 0.867) and rs4810485
G/T (|D'| = 0.841). The rs1569723 A/C and rs4810485
G/T were in strong linkage disequilibrium (|D'| = 0.922).
By haplotype analyses, we found T-C-T haplotype was
associated with a significantly increased risk of SLE as
Fig. 1 The levels of CD40 in patients with SLE and normal control
subjects. The expression of CD40 was significantly increased in patients
with SLE compared to that in control subjects [(mean +/− SD 41.7+/−
13.2 pg/ml, n = 205) vs (mean +/− SD 58.5+/− 22.8 pg/ml, n = 220);
P <0.001]
Table 2 The genotype and allele frequencies of CD40
polymorphism in SLE patients and controls
Polymorphism Control subjects
n = 220 (%)
SLE patients
n = 205 (%)
χ2 P value
rs1883832 C/T
CC 79 (35.9) 47 (22.9) 9.504 0.009
CT 101 (45.9) 105 (51.2)
TT 40 (18.2) 53 (25.9)
C 259 (58.9) 199 (48.5) 9.109 0.003
T 181 (41.1) 211 (51.5)
rs1569723 A/C
AA 54 (24.5) 51 (24.9) 0.284 0.868
AC 105 (47.7) 93 (45.4)
CC 61 (27.7) 61 (29.8)
A 213 (48.4) 195 (47.6) 0.061 0.805
C 227 (51.6) 215 (52.4)
rs4810485 G/T
GG 56 (25.5) 52 (25.4) 0.341 0.843
GT 107 (48.6) 95 (46.3)
TT 57 (25.9) 58 (28.3)
G 219 (49.8) 199 (48.5) 0.130 0.719
T 221 (50.2) 211 (51.5)
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compared with the control group (OR = 1.408; 95 % CI,
1.074–1.845; P = 0.013).
Association between CD40 gene polymorphisms and
sCD40 levels
Genotype at the rs1883832 C/T polymorphism was sig-
nificantly associated with sCD40 levels in patients with
SLE. The plasma CD40 levels were significantly higher
in individuals with homozygous TT genotypes (62.6 +/−
23.3 pg/ml, n = 53) or heterozygous of CT genotypes
(59.9 +/− 22.6 pg/ml, n = 105) than homozygous of CC
genotypes (50.7 +/− 20.4 pg/ml, n = 47, P < 0.01, re-
spectively). However, there were no significant differ-
ences in the plasma CD40 levels between TT and CT
genotypes (Fig. 2). In addition, there were no signifi-
cant associations of the CD40 rs1569723 A/C and
rs4810485 G/T polymorphisms with plasma levels of
CD40 (data not shown).
Discussion
CD40, the receptor for CD40L, is a 48-kDa transmem-
brane protein belonging to the TNF (tumor necrosis
factor) superfamily, and is expressed on B cells, endothe-
lial cells, macrophages, dendritic cells, T cells, and fibro-
blasts. Until now, little information has addressed the
association between CD40 polymorphisms and its sol-
uble level in Chinese patients. In this study, we focused
on identifying a genetic marker that may help refine the
SLE risk profile. We found that the rs1883832 C/T
polymorphism of CD40 and the levels of sCD40 were
significantly associated with the presence of SLE. The
rs1883832 C/T polymorphism may affect the levels of
sCD40. Moreover, we also found that the rs1883832 C/T
polymorphism was in strong linkage disequilibrium with
the rs1569723 A/C (|D'| = 0.867) and rs4810485 G/T
(|D'| = 0.841). The rs1569723 A/C and rs4810485 G/T
were in strong linkage disequilibrium (|D'| = 0.922).
Major two haplotype frequencies of the TCT and CAG
among the SLE in the present study were 0.515 and
0.429 respectively. By haplotype analyses, we found that
TCT haplotype was associated with a significantly in-
creased risk of SLE as compared with the control groups
(OR = 1.408; 95 % CI, 1.074–1.845; P = 0.013). Our re-
sults suggest that the CD40 gene plays a central role in
the mechanism of the SLE pathophysiology. Thus, CD40
gene rs1883832 C/T polymorphism may serve as novel
genetic markers of susceptibility to SLE in the Chinese
population.
SLE is a chronic inflammatory disease of collagen in the
skin, of joints, and of internal organs, and is a complex
disorder in which multiple genetic variants, together with
environmental and hormonal factors, contribute to disease
risk. The etiology of SLE remains unknown, and the
pathological mechanisms underlying the related organ
and tissue damage have not been fully elucidated [26].
Recently, increasing evidence showed that CD40 contrib-
utes to the pathogenesis of chronic inflammatory and
autoimmune diseases due to its biological activity [27]. In
several reports of SLE, CD40 has either been indirectly or
directly shown to be a contributing factor to the disease.
In one report, Zhang et al. presented that TT genotype
carriers showed higher CD40 expression and serum




2 n = 410 (%)
Controls
2 n = 440 (%)
OR (95 % CI) P value
T-C-T 211 (51.5) 189 (43.0) 1.408 (1.074–1.845) 0.013
C-A-G 176 (42.9) 207 (47.0) 0.847 (0.646–1.110) 0.228
C-A-T 8 (2.0) 13 (3.0) 0.735 (0.253–2.138) 0.346
C-C-G 6 (1.5) 14 (3.2) 0.452 (0.172–1.187) 0.099
C-C-T 4 (1.0) 8 (1.8) 0.532 (0.159–1.780) 0.298
T-A-T 5 (1.2) 9 (2.0) 0.591 (0.196–1.779) 0.344
Fig. 2 Association between the levels of CD40 and the rs1883832
C/T polymorphism of CD40 gene was observed in patients with SLE.
Plasma CD40 levels with CC homozygous were significantly lower
than that of the TT homozygous or CT heterozygotes, respectively.
However, there were no significant differences in the plasma CD40
levels between CT and TT genotypes
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soluble CD40 ncentration in male IS patients [28]. CD40
polymorphisms are also associated with SLE clinical mani-
festation, mainly nephritis and arthritis [29, 30]. However,
Plasma levels of CD40 were significantly elevated in SLE
patients in comparison with healthy controls. In the
present study, our data also showed that the plasma
sCD40 levels were significantly high in SLE patients com-
pared to controls. The results of our study indirectly
suggest that CD40 may play a role in patients with SLE.
These observations make CD40 an interesting candidate
gene for a role in human SLE.
Several studies have investigated associations between
genetic variation in the CD40 gene and SLE, but results
of these studies have been inconsistent. Vazgiourakis
found that CD40 has been identified as a new suscepti-
bility locus in Greek and Turkish patients with SLE. The
rs4810485 minor allele T is under-represented in SLE
and correlates with reduced CD40 expression in per-
ipheral blood monocytes and B cells, with potential
implications for the regulation of aberrant immune re-
sponses in the disease, the CD40 gene rs4810485 G/T
polymorphisms between the group of patients with SLE
and the control group in European-American population
(P < 0.05) [31]. Meanwhile, Piotrowski reported that there
was no apparent relationship in the genotype frequencies
of CD40 gene rs4810485 G/T polymorphisms with the
risk of SLE in Polish patients as compared to controls
(P > 0.05) [32]. Our results showed that there were
significant differences in the genotype and allele fre-
quencies of CD40 gene rs1883832C/T polymorphism
between the group of patients with SLE and the control
group (P < 0.05). sCD40 levels were increased in
patients with SLE compared with controls (P < 0.01).
The rs1883832C/T polymorphism of CD40 and its
sCD40 levels were associated with SLE in the Chinese
population. However their findings suggest that the sig-
nificant variation in prevalence of risk genetic locis
among different populations may also explain some of
the sizable geographic variation in disease prevalence.
The reason for these discrepancies remains unclear, but
several possibilities should be considered. First, it may be
due to the genetic trait differences; CD40 gene polymor-
phisms were distinct in specific population, various eth-
nicities and geographic region. Furthermore, SLE is a
multi-factorial disease and individual exposure to various
environmental factors, and genetic susceptibility might
have caused different results. In addition, the inadequate
study design such as non-random sampling and a limited
sample size should also be considered. The possible selec-
tion bias that might have been present in the hospital-
based, case–control study is a relevant issue. Finally, we
cannot exclude that the observed association depends on
a gene in linkage disequilibrium with the CD40 gene or
on the effect of CD40 on another peptide.
So far, investigations on the CD40 gene rs1883832 C/T
polymorphism and its soluble level, which are associated
with SLE, have not been performed. Our data demon-
strated that CD40 gene rs1883832 C/T polymorphism
was associated with SLE (P < 0.05). Also, the level of
sCD40 was found to be elevated in SLE patients (P < 0.01).
Moreover, genotypes carrying the CD40 rs1883832 C/T
variant allele (TT or CT genotype) were associated with
increased CD40 levels compared to the homozygous
wild-type genotype (CC genotype) in patients with
SLE (P <0.01). Additionally, our results showed that
sCD40 levels were not associated with the polymor-
phisms of the CD40 in healthy controls. A plausible
explanation is that the sCD40 expression is inducible
and its expression is upregulated after stimulation and
such inflammatory stimulation in healthy controls should
be missing. However, we found that individuals carrying
the rs1883832 T allele of the CD40 gene rs1883832 C/T
polymorphism, which has been associated with increased
sCD40 production, were at a significantly increased risk of
SLE. This finding suggests an association between CD40
genotypes and its soluble form. We speculate that CD40
gene rs1883832 C/T polymorphismmay exert an impact
on its protein metabolism and stability.
Conclusion
On the basis of these findings, we conclude that the
rs1883832 C/T polymorphism of CD40 and the levels of
sCD40 were significantly associated with the risk of SLE
in the Chinese population. These results suggest that
further studies with larger cohorts of patients should be
performed to illustrate the correlation of the CD40 gene
polymorphism with SLE susceptibility, independently or
in combination with other CD40 SNPs and other genes.
Because genetic polymorphisms were often vary different
between ethnic groups, further studies are also needed
to clarify the association of the CD40 polymorphism
with the risk of SLE in diverse ethnic populations.
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